Everolimus trials for HER2-negative Breast Cancer

All Everolimus trials · All HER2-negative Breast Cancer trials

Phase breakdown

Recruiting trials studying Everolimus for HER2-negative Breast Cancer

• Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
  NCT06382948 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 104 locations
• Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
  NCT05508906 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• SNF Platform Study of HR+/ HER2-advanced Breast Cancer
  NCT05594095 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location

Common questions

How many trials study Everolimus for HER2-negative Breast Cancer?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.